Scientific recommendations on classification of advanced therapy medicinal products

Human medicines European public assessment report (EPAR): Pixuvri, pixantrone dimaleate, Date of authorisation: 10/05/2012, Revision: 23, Status: Expired

Aplidin

Agenda - Public webinar on pack size submissions: from XEVMPD to product management service (PMS)

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Status: Authorised

Fourth veterinary big data stakeholder forum, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 October 2024, 10:00 (CEST) to 14 October 2024, 15:00 (CEST)

Human medicines European public assessment report (EPAR): Giapreza, angiotensin II, Date of authorisation: 23/08/2019, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zevalin, ibritumomab tiuxetan, Date of authorisation: 16/01/2004, Revision: 23, Status: Lapsed

Opinion/decision on a Paediatric investigation plan (PIP): onivyde, irinotecan, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0241/2023

EMEA-003408-PIP01-23